
Ngx Bio
Marketplace for online DNA sequencing services.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | $3.0m | Early VC | |
Total Funding | 000k |
USD | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | (17 %) | - | (20 %) |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
NGX Bio operates in the biotechnology sector, specializing in next-generation sequencing (NGS) services. The company serves a wide range of clients, including academic researchers, pharmaceutical companies, and clinical laboratories. NGX Bio's business model revolves around providing high-quality sequencing data with a fast turnaround time, which is crucial for timely analysis and decision-making in research and clinical settings. The company generates revenue by offering competitive pricing for its sequencing services, which include immuno-oncology, biomarker discovery, clinical test qualification, and various genetic tests. NGX Bio's market is primarily focused on precision medicine, cancer treatment, and pharmacogenomics, where accurate and rapid genetic data is essential. The company is known for its reliability, responsiveness, and the ability to handle projects of any scale, making it a preferred choice among its clients.
Keywords: next-generation sequencing, biotechnology, genetic analysis, precision medicine, cancer treatment, pharmacogenomics, rapid turnaround, high-quality data, competitive pricing, clinical laboratories.